Envisagenics

What Envisagenics does

Envisagenics, Inc. is a privately held biotechnology company founded in 2014 as a spinout of Cold Spring Harbor Laboratory and headquartered in Long Island City, New York. The company applies artificial intelligence to RNA splicing biology to discover and develop therapeutic targets in oncology and neurodegenerative diseases. Its core product is SpliceCore®, a cloud-based AI/ML platform that processes RNA-sequencing data through an exon-centric architecture and a proprietary database of more than 14 million RNA splicing events to identify disease-specific splicing events with high therapeutic potential; the company reports a 70% experimental validation rate and claims discovery rates up to 250x higher than gene-centric tools. SpliceIO™, a complementary module, applies machine learning to identify tumor-specific splicing-derived neoepitopes for immuno-oncology applications. Envisagenics also advances an internal pipeline of antisense and splice-switching oligonucleotide candidates, including ENV-375 and ENV-378 for amyotrophic lateral sclerosis (with extensions into frontotemporal dementia, Alzheimer's, and Parkinson's), and the previously disclosed ENV-0205 for triple negative breast cancer. The founding scientific team contributed to the development of SPINRAZA®, the first FDA-approved RNA splicing therapeutic.

Envisagenics operates a hybrid business model combining a platform-as-a-product offering with biopharma collaborations and internal drug development. Commercial revenue is generated primarily through multi-year research collaborations with biopharmaceutical companies — including Bristol Myers Squibb (oncology, announced November 2022), Biogen (CNS, May 2021), and the Johnson & Johnson Lung Cancer Initiative (lung cancer, January 2020) — typically structured as upfront payments plus milestone payments tied to development, regulatory, and commercial achievements. The SpliceCore platform has been commercially available since October 2017 and was described in the June 2024 Series B press release as generating revenue, with the company itself characterized as 'profitable.' Non-dilutive capital from NIH/NCI SBIR grants (cumulative ~$4 million across 2015, 2018, 2020, and 2022) has supplemented equity funding from a syndicate including Red Cell Partners, Third Kind Venture Capital, M12 (Microsoft's venture fund), Madrona Venture Group, Dynamk Capital, Empire State Development, Dolby Family Ventures, SV Angel, and Breakout Labs.

The company serves two customer categories: biopharmaceutical partners seeking AI-enabled target discovery and validation, and (via its internal pipeline) the broader patient population in oncology and neurodegenerative disease. Go-to-market is enterprise field sales to pharma discovery and translational science groups, complemented by academic collaborations that generate validation data and expand the platform's reach into institutions including Memorial Sloan Kettering, Northwestern University, Cold Spring Harbor Laboratory, and Queen Mary University of London (via Cancer Research Horizons). As of November 2017, headcount was 8 employees; the company is now in the 11-50 employee band per firmographic data, and was described as profitable at the time of its $25 million Series B close in June 2024 with strategic investor Bristol Myers Squibb.

Name

Envisagenics

Legal name

Envisagenics, Inc.

Website

https://envisagenics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Envisagenics is a privately held, profitable AI/ML biotech that uses its SpliceCore® platform to decode RNA splicing and discover novel therapeutic targets in oncology and neurodegenerative diseases for biopharmaceutical partners, while advancing an internal antisense oligonucleotide pipeline.

Ownership category

akta.pro rank

Product category

AI-driven RNA splicing drug discovery platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• AI drug discovery
• RNA splicing therapeutics
• Antisense oligonucleotide discovery
• Biomedical data analysis
• Immuno-oncology target identification

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Biopharma research collaboration upfront and milestone payments: Multi-year research collaboration agreements with biopharmaceutical companies include an upfront payment plus milestone payments tied to development, regulatory, and commercial achievements. Example: Bristol Myers Squibb multi-year oncology collaboration (announced November 2022).
2. Platform commercial offerings / discovery services: Commercial offerings built on the SpliceCore platform (described in Series B announcement as a revenue-generating biotech). SpliceCore has been commercially validated by multiple biopharma leaders and has been demoed at industry events as a commercial product since 2017.
3. Non-dilutive grant funding (NIH/NCI SBIR): SBIR Phase I ($300K, 2019) and SBIR Direct to Phase II ($2M, 2022) grants from the National Cancer Institute, plus a $1.5M Phase II SBIR grant from NIH/NIGMS (2018), used to fund platform development and commercialization.

Pricing tiers

Go-to-market motion1 record

Core offering

Envisagenics operates a cloud-based AI/ML drug discovery platform (SpliceCore®) that analyzes RNA-sequencing data to identify disease-specific alternative splicing events and prioritize therapeutic targets, with a complementary module (SpliceIO™) for immuno-oncology neoantigen discovery. The company monetizes the platform through multi-year research collaborations with biopharmaceutical companies and is internally advancing a preclinical pipeline of antisense and splice-switching oligonucleotide therapeutics for oncology and neurodegenerative diseases.

Product overview

Envisagenics offers a platform-plus-modules architecture centered on SpliceCore®, its proprietary cloud-based AI/ML drug discovery platform for decoding RNA splicing complexity and identifying validated therapeutic targets in oncology, neurodegeneration, and other high-need indications. SpliceCore serves as the core engine, processing RNA-seq data through an exon-centric ML approach against a proprietary database of more than 14 million RNA splicing events to discover novel, disease-specific targets. SpliceIO™ operates as a complementary module extending SpliceCore's capabilities into immuno-oncology by discovering tumor-specific RNA splicing-derived neoantigens for immunotherapy development. Building on these discovery capabilities, Envisagenics is advancing a pipeline of internally developed antisense oligonucleotide therapeutic candidates — including ENV-375 (for ALS, with extensions into FTD/AD/PD), ENV-378 (for ALS), and the previously disclosed ENV-0205 (for TNBC) — to translate AI-discovered targets into disease-modifying RNA therapeutics. The platform has been commercially validated through research collaborations and licensing arrangements with Biogen, Bristol Myers Squibb, Johnson & Johnson, Cancer Research Horizons, and others.

Differentiator

Problem solved

Functional benefit

Brands

• SpliceCore®: Envisagenics' proprietary AI/ML drug discovery platform that discovers novel, prevalent, and disease-specific RNA splicing events with high therapeutic potential. The platform analyzes more than 14 million RNA splicing events and is used both internally and in biopharma partnerships.
• SpliceIO™

Products and services

• SpliceCore® Envisagenics' proprietary cloud-based AI/ML platform that discovers novel, prevalent, disease-specific RNA splicing events with high therapeutic potential. Maintains a database of more than 14 million RNA splicing events and is sold to biopharma customers via research collaborations.
• SpliceIO™ Machine learning module that identifies tumor-specific RNA splicing-derived neoantigens from RNA-seq data for first-in-class immunotherapy candidate development. Sold as a commercial offering complementing SpliceCore.
• ENV-375 Preclinical antisense oligonucleotide therapeutic candidate for Amyotrophic Lateral Sclerosis (ALS), also being developed for frontotemporal dementia (FTD), Alzheimer's disease (AD), and Parkinson's disease (PD). Targets RNA splicing errors in the CNS.
• ENV-378 Preclinical antisense oligonucleotide therapeutic candidate for Amyotrophic Lateral Sclerosis (ALS), part of the company's CNS therapeutic pipeline targeting RNA splicing errors.
• ENV-0205 Preclinical splice-switching oligonucleotide therapeutic candidate for the treatment of triple negative breast cancer (TNBC), identified by the SpliceCore platform.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Schrödinger: Computational chemistry and predictive analytics platform for drug discovery, serving large pharma via software subscriptions and co-development deals. Comparable in selling computational/AI tooling to pharma R&D and operating an internal pipeline, but at much larger scale.
• Ionis Pharmaceuticals: Established leader in antisense oligonucleotide drug discovery with multiple marketed and clinical-stage RNA-targeted therapies. Comparable as a reference point for the therapeutic modality Envisagenics is pursuing with its preclinical pipeline.
• Exscientia: AI-driven small-molecule drug discovery company with multiple pharma collaborations and internal pipeline assets. Comparable as a publicly listed AI-drug-discovery platform that monetizes via research collaborations and partnered assets.
• BenevolentAI: AI-driven drug discovery company with pharma collaborations (e.g., AstraZeneca, Merck KGaA) and a small internal pipeline. Comparable as an AI-platform-led biotech monetizing through pharma partnerships.
• Recursion Pharmaceuticals: Public AI-driven drug discovery platform combining high-throughput biology with machine learning. Like Envisagenics, it sells platform-derived collaborations to large pharma and pursues an internal pipeline, but operates at vastly larger scale and across broader therapeutic areas.
• Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind-derived computational approaches to pharma R&D, with major partnerships (Eli Lilly, Novartis). Represents a well-capitalized potential competitor that could draw SpliceCore's pharma partners if it extends into RNA splicing.
• Insitro: Machine-learning-driven drug discovery company with pharma partnerships (e.g., Bristol Myers Squibb, Eli Lilly) and an internal pipeline focused on neuroscience and metabolic disease. Closely comparable business model to Envisagenics as a platform-plus-pipeline AI biotech, but with broader disease scope.

Emerging players

• Deep Genomics: AI platform focused on RNA biology for oligonucleotide-based drug discovery. Closely comparable technology overlap with SpliceCore in using ML on RNA to identify therapeutic targets, with a similar platform-plus-pipeline model.
• Owkin: AI-for-biomedicine company applying machine learning to multi-modal patient data for drug discovery and clinical research, with pharma partnerships (e.g., Bristol Myers Squibb). Comparable as a biomedical AI platform serving pharma R&D; overlaps thematically but not directly in RNA splicing.

Direct peers

• Stoke Therapeutics: Clinical-stage biotech developing antisense oligonucleotide medicines that modulate RNA splicing (e.g., STK-001 for Dravet syndrome). The most direct therapeutic-area competitor to Envisagenics, with a more advanced pipeline but a less differentiated discovery platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCyzyw9O8KRUPOcDeyzu80Sg
• LinkedInlinkedin.com/company/envisagenics
• Xx.com/envisagenics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds14 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Envisagenics